Summary Safety Review - PRADAXA (dabigatran etexilate) - Assessing the potential risk of liver injury

Health Canada reviewed the potential risk of liver injury with Pradaxa after receiving reports of severe liver injury from the manufacturer. The manufacturer was asked to provide all available data on Pradaxa and the risk of liver injury.

Données et ressources

Info additionnelle

Champ Valeur
Source
Version
Producteur
Courriel de l'auteur
Mainteneur
Courriel du mainteneur
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Résumé de l’examen de l’innocuité - PRADAXA (dabigatran étexilate) - Évaluation du risque potentiel de lésions du foie
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Langue
Contact Person
Contact Email
Dictionnaire de données
Open Canada Date Published 2018-05-07 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["Résumé de l'examen de l'innocuité", "PRADAXA", "dabigatran etexilate", "évaluation", "risque potentiel", "lésion hépatique"], "en": ["Summary Safety Review", "PRADAXA", "dabigatran etexilate", "assessing", "potential risk", "liver injury"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source